[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054111":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":27,"centralContacts":34,"locations":40,"responsibleParty":110,"collaborators":27,"id":112,"slug":27,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":27,"eligibilityCriteria":117,"healthyVolunteers":113,"sex":118,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":27,"studyType":124,"phases":125,"briefSummary":128,"conditions":129,"keywords":27,"overallStatus":43,"whyStopped":27,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"TORL Biotherapeutics, LLC","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Arm A: TORL-1-23 and paclitaxel","EXPERIMENTAL","Administered once every three weeks",[13],"Combination Product: TORL-1-23 and paclitaxel",{"label":15,"type":10,"description":11,"interventionNames":16},"Treatment Arm B: TORL-1-23 and carboplatin",[17],"Combination Product: TORL-1-23 and carboplatin",{"label":19,"type":10,"description":11,"interventionNames":20},"Treatment Arm C: TORL-1-23, paclitaxel, and carboplatin",[21],"Combination Product: TORL-1-23, paclitaxel, and carboplatin",[23,28,31],{"type":24,"name":25,"description":25,"armGroupLabels":26,"otherNames":27},"COMBINATION_PRODUCT","TORL-1-23 and paclitaxel",[9],null,{"type":24,"name":29,"description":29,"armGroupLabels":30,"otherNames":27},"TORL-1-23 and carboplatin",[15],{"type":24,"name":32,"description":32,"armGroupLabels":33,"otherNames":27},"TORL-1-23, paclitaxel, and carboplatin",[19],[35],{"name":36,"role":37,"phone":38,"phoneExt":27,"email":39},"Caroline Labib, PharmD","CONTACT","310-348-9636","caroline.labib@torlbio.com",[41,54,63,72,81,91,100],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":27},"Providence St. Jude Medical Center","RECRUITING","Fullerton","California","92835","United States",{"type":49,"coordinates":50},"Point",[51,52],-117.92534,33.87029,{"lat":52,"lon":51},{"facility":55,"status":43,"city":56,"state":45,"zip":57,"country":47,"cosmosGeoPoint":58,"geoPoint":62,"contacts":27},"City of Hope","Irvine","92618",{"type":49,"coordinates":59},[60,61],-117.82311,33.66946,{"lat":61,"lon":60},{"facility":64,"status":43,"city":65,"state":45,"zip":66,"country":47,"cosmosGeoPoint":67,"geoPoint":71,"contacts":27},"University of Southern California","Los Angeles","90007",{"type":49,"coordinates":68},[69,70],-118.24368,34.05223,{"lat":70,"lon":69},{"facility":73,"status":43,"city":65,"state":45,"zip":74,"country":47,"cosmosGeoPoint":75,"geoPoint":77,"contacts":78},"UCLA","90095",{"type":49,"coordinates":76},[69,70],{"lat":70,"lon":69},[79],{"name":80,"role":37,"phone":38,"phoneExt":27,"email":27},"Principal Investigator",{"facility":82,"status":43,"city":83,"state":84,"zip":85,"country":47,"cosmosGeoPoint":86,"geoPoint":90,"contacts":27},"The Mayo Clinic","Rochester","Minnesota","55905",{"type":49,"coordinates":87},[88,89],-92.4699,44.02163,{"lat":89,"lon":88},{"facility":92,"status":43,"city":93,"state":93,"zip":94,"country":47,"cosmosGeoPoint":95,"geoPoint":99,"contacts":27},"Mt Sinai Hospital","New York","10029",{"type":49,"coordinates":96},[97,98],-74.00597,40.71427,{"lat":98,"lon":97},{"facility":101,"status":43,"city":102,"state":103,"zip":104,"country":47,"cosmosGeoPoint":105,"geoPoint":109,"contacts":27},"Duke University","Durham","North Carolina","27705",{"type":49,"coordinates":106},[107,108],-78.89862,35.99403,{"lat":108,"lon":107},{"type":111,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100054111",false,"NCT07322094","CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer","CATALINA-4: Phase 1B\u002F2 Study of TORL-1-23 With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Newly Diagnosed Patients With Advanced Stage Ovarian Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1\n* Histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tubes cancer\n* FIGO Stage III or IV\n* Positive for claudin 6 (CLDN6) expression\n* Adequate organ function\n\nExclusion Criteria:\n\n* Clear cell, mucinous, sarcomatous, mixed histology, low-grade\u002Fborderline, or non-epithelial ovarian cancers\n* Prior systemic treatment for the disease under study\n* Prior surgery\n* Prior radiation therapy to the abdomen or pelvis\n* Current recipient or receipt within 5-half-lives of C1D1 of any of the following: chemotherapy, biologic\u002Ftargeted therapy, herbal medications or supplements, immunomodulator therapy for any disease indication.\n* History of noninfectious pneumonitis\u002Finterstitial lung disease (ILD) within 6 months of first dose of study drug.\n* Active, progressive, or symptomatic brain metastases\n* Participants considered poor medical risks due to serious, uncontrolled medical conditions, active infections, or nonmalignant systemic diseases\n* Pregnant or breastfeeding women","FEMALE","18 Years","75 Years",{"count":122,"type":123},60,"ESTIMATED","INTERVENTIONAL",[126,127],"PHASE1","PHASE2","A Phase 1B\u002F2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer",[130,131,132],"FIGO Stage III and IV Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer","2026-07-09",{"date":135,"type":136},"2026-07-13","ACTUAL",{"date":138,"type":136},"2025-12-10",{"date":140,"type":123},"2028-01",{"name":5,"class":6},7]